Total Payments
$270,667
2024 Payments
$38,037
Companies
24
Transactions
181
Medicare Patients
1,142
Medicare Billing
$248,872
Payment Breakdown by Category
Consulting$164,227 (60.7%)
Other$47,437 (17.5%)
Travel$36,408 (13.5%)
Research$19,098 (7.1%)
Food & Beverage$3,397 (1.3%)
Education$99.95 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $164,227 | 58 | 60.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,607 | 10 | 16.1% |
| Travel and Lodging | $36,408 | 42 | 13.5% |
| Unspecified | $19,098 | 23 | 7.1% |
| Food and Beverage | $3,397 | 45 | 1.3% |
| Honoraria | $2,325 | 1 | 0.9% |
| Grant | $1,506 | 1 | 0.6% |
| Education | $99.95 | 1 | 0.0% |
Payments by Type
General
$251,569
158 transactions
Research
$19,098
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $58,390 | 26 | $0 (2024) |
| Amgen Inc. | $41,401 | 24 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $29,707 | 19 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $26,966 | 14 | $0 (2017) |
| Regeneron Pharmaceuticals, Inc. | $22,763 | 9 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $20,275 | 13 | $0 (2022) |
| Celgene Corporation | $19,059 | 12 | $0 (2021) |
| Janssen Biotech, Inc. | $12,255 | 12 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $8,561 | 14 | $0 (2024) |
| PFIZER INC. | $6,847 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,037 | 19 | GENZYME CORPORATION ($37,898) |
| 2023 | $19,246 | 14 | PFIZER INC. ($5,698) |
| 2022 | $45,313 | 24 | Regeneron Pharmaceuticals, Inc. ($14,328) |
| 2021 | $19,638 | 11 | Celgene Corporation ($5,175) |
| 2020 | $30,025 | 14 | GENZYME CORPORATION ($10,066) |
| 2019 | $41,972 | 19 | Amgen Inc. ($21,694) |
| 2018 | $33,871 | 45 | Amgen Inc. ($11,445) |
| 2017 | $42,564 | 35 | Millennium Pharmaceuticals, Inc. ($26,966) |
All Payment Transactions
181 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 12/07/2024 | GENZYME CORPORATION | SARCLISA (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant • Category: Oncology | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $79.00 | General |
| 11/05/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant • Category: Oncology | ||||||
| 10/02/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $15,568.00 | General |
| Category: Oncology | ||||||
| 10/02/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $339.59 | General |
| Category: Oncology | ||||||
| 10/02/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $148.47 | General |
| Category: Oncology | ||||||
| 10/02/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | Cash or cash equivalent | $75.32 | General |
| Category: Oncology | ||||||
| 09/25/2024 | GENZYME CORPORATION | SARCLISA (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant • Category: Oncology | ||||||
| 08/23/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $96.59 | General |
| Category: Oncology | ||||||
| 07/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $15,568.00 | General |
| Category: Oncology | ||||||
| 07/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $311.21 | General |
| Category: Oncology | ||||||
| 07/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $270.07 | General |
| Category: Oncology | ||||||
| 07/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $167.17 | General |
| Category: Oncology | ||||||
| 06/03/2024 | GENZYME CORPORATION | SARCLISA (Biological) | — | In-kind items and services | $1,250.00 | Research |
| Study: A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant • Category: Oncology | ||||||
| 06/03/2024 | GENZYME CORPORATION | SARCLISA (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant • Category: Oncology | ||||||
| 06/03/2024 | GENZYME CORPORATION | SARCLISA (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant • Category: Oncology | ||||||
| 04/11/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,854.00 | General |
| 10/19/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,100.00 | General |
| 09/26/2023 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| 09/26/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $69.46 | General |
| 09/26/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $12.79 | General |
| 09/26/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $7.47 | General |
| 08/16/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 4220 - CFZ Ph3 H2H vs Velcade (2011-003) ENDEAVOR | Amgen Inc. | $3,840 | 3 |
| The BiTE (Bispecific T Cell Engager) Platform: Development and Future Potential of a Targeted Imm | Amgen Inc. | $3,539 | 1 |
| A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant | GENZYME CORPORATION | $3,250 | 6 |
| Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). | SANOFI-AVENTIS U.S. LLC | $1,969 | 2 |
| REGN5458 Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $1,556 | 2 |
| A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ORAL IXAZOMIB MAINTENANCE THERAPY AFTER INITIAL THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA NOT TREATED WITH STEM CELL TRANSPLANTATION | Takeda Pharmaceuticals U.S.A., Inc. | $1,442 | 2 |
| A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ORAL IXAZOMIB CITRATE (MLN9708) MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT | Takeda Pharmaceuticals U.S.A., Inc. | $1,285 | 2 |
| TRILLIUM CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| MEDI4736-MM-005 | Celgene Corporation | $417.00 | 1 |
| 4300 - CFZ Ph1b/2 CHAMPION #1 (2012-002) | Amgen Inc. | $393.52 | 1 |
| REGN5458 CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $291.65 | 1 |
| Supervivencia global de pacientes con mieloma multiple en recaida o refractario tratados con carfilzomib | Amgen Inc. | $175.65 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 351 | 742 | $322,172 | $74,288 |
| 2022 | 8 | 332 | 737 | $302,537 | $73,322 |
| 2021 | 4 | 201 | 476 | $207,466 | $49,855 |
| 2020 | 8 | 258 | 585 | $233,503 | $51,407 |
Total Patients
1,142
Total Services
2,540
Medicare Billing
$248,872
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 132 | 394 | $210,198 | $43,237 | 20.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 139 | $39,917 | $12,988 | 32.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 49 | 64 | $16,988 | $4,474 | 26.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 30 | $18,163 | $4,141 | 22.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 24 | 24 | $13,396 | $3,165 | 23.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 28 | 30 | $9,804 | $2,642 | 26.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 28 | $6,332 | $1,753 | 27.7% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2023 | 21 | 21 | $5,304 | $1,249 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 12 | $2,070 | $639.24 | 30.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 126 | 359 | $184,869 | $40,232 | 21.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 42 | 164 | $46,412 | $13,306 | 28.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 37 | 38 | $21,218 | $6,042 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 49 | 65 | $16,590 | $4,992 | 30.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 29 | 31 | $9,544 | $2,642 | 27.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $10,306 | $2,558 | 24.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 42 | $8,988 | $2,461 | 27.4% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2022 | 19 | 19 | $4,610 | $1,088 | 23.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 111 | 355 | $175,647 | $40,485 | 23.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 54 | 71 | $17,407 | $5,062 | 29.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $9,360 | $2,751 | 29.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 18 | 32 | $5,052 | $1,557 | 30.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 112 | 312 | $148,981 | $26,706 | 17.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 34 | 145 | $41,035 | $11,986 | 29.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 29 | 32 | $16,450 | $5,211 | 31.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 16 | 16 | $8,390 | $2,241 | 26.7% |
About Dr. Robert Orlowski, MD
Dr. Robert Orlowski, MD is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336209956.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Orlowski, MD has received a total of $270,667 in payments from pharmaceutical and medical device companies, with $38,037 received in 2024. These payments were reported across 181 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($164,227).
As a Medicare-enrolled provider, Orlowski has provided services to 1,142 Medicare beneficiaries, totaling 2,540 services with total Medicare billing of $248,872. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Houston, TX
- Active Since 12/12/2006
- Last Updated 08/27/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1336209956
Products in Payments
- SARCLISA (Biological) $64,596
- NINLARO (Drug) $29,131
- Kyprolis (Biological) $26,499
- Blincyto (Biological) $9,145
- DARZALEX (Biological) $7,605
- ICLUSIG (Drug) $7,240
- EMPLICITI (Biological) $6,823
- CD38 (Drug) $5,376
- Pomalyst (Drug) $5,175
- SAR650984 (Drug) $5,029
- TECVAYLI (Biological) $4,650
- ISATUXIMAB (Drug) $3,982
- XPOVIO (Drug) $2,430
- VENCLEXTA (Drug) $2,025
- clonoSEQ (Device) $2,000
- DARZALEX (Drug) $1,874
- Nplate (Biological) $825.00
- Durvalumab (Drug) $417.00
- Kyprolis (Drug) $275.00
- ZYTIGA (Drug) $99.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001